AHMED ABDEL-LATIF, M.D.
Osteopathic Medicine at Rose St, Lexington, KY
License number
Kentucky 38574
Category
Osteopathic Medicine
Type
Interventional Cardiology
License number
Kentucky 38574
Category
Osteopathic Medicine
Type
Cardiovascular Disease
Address
Address
800 Rose St STE. G100, Lexington, KY 40536
Phone
(859) 323-0295
(859) 323-1256 (Fax)
(859) 218-5677
(859) 257-7899 (Fax)
(859) 323-1256 (Fax)
(859) 218-5677
(859) 257-7899 (Fax)
Organization information
See more information about AHMED ABDEL-LATIF at bizstanding.comAhmed Abdel-Latif MD
800 Rose St, Lexington, KY 40536
Industry:
Internist
Phone:
(859) 323-0295 (Phone)
Ahmed Kamal Abdel-Latif
Professional information
Dr. Ahmed K Abdel-Latif, Lexington KY - MD (Doctor of Medicine)
Specialties:
Cardiology, Interventional Cardiology
Age:
49
Address:
800 Rose St, Lexington 40536
(859) 323-0295 (Phone), (859) 323-1256 (Fax)
(859) 323-0295 (Phone), (859) 323-1256 (Fax)
Certifications:
Cardiovascular Disease, 2008, Internal Medicine, 2004, Interventional Cardiology, 2009
Awards:
Healthgrades Honor Roll
Languages:
English
Education:
Fellowship Hospital
University Louisville
University Louisville
Ahmed Kabdel Abdel-Latif, Lexington KY
Specialties:
Cardiologist
Address:
Gill Heart Institute University Of Kentucky, Lexington, KY 40536
Subpopulations Of Bone Marrow-Derived Adherent Stem Cells And Methods Of Use Therefor
US Patent:
2009011, Apr 30, 2009
Filed:
Oct 30, 2008
Appl. No.:
12/261344
Inventors:
Buddhadeb Dawn - Louisville KY, US
Ahmed Abdel-Latif - Lexington KY, US
Roberto Bolli - Louisville KY, US
Ahmed Abdel-Latif - Lexington KY, US
Roberto Bolli - Louisville KY, US
Assignee:
The University of Louisville Research Foundation, Inc. - Louisville KY
International Classification:
A61K 35/12, C12N 5/06
US Classification:
424 937, 435378, 435325
Abstract:
The presently disclosed subject matter provides an isolated subpopulation of bone marrow-derived adherent stem cells that are purified from bone marrow-derived adherent cells. Also provided are methods for isolating the subpopulation of bone marrow-derived adherent stem cells from bone marrow-derived adherent cells and for using the isolated subpopulation of bone marrow-derived adherent stem cells for treating tissue and/or organ damage in a subject.